Skip to main content
. Author manuscript; available in PMC: 2016 Mar 10.
Published in final edited form as: Nat Rev Gastroenterol Hepatol. 2015 Jun 30;12(8):446–457. doi: 10.1038/nrgastro.2015.111

Table 2.

Potential antidiarrhoeal therapies

Name/class Target and mechanism Potential indication Development stage
Antisecretory factor Inhibition of enteric nervous system; increased epithelial permeability Acute secretory diarrhoea Phase III
CaCCinh-A01 Absorbable CaCC inhibitor Acute secretory diarrhoea Preclinical
iOWH032 Extracellular-acting CFTR inhibitor Acute secretory diarrhoea Phase I
CFTRinh-172 Absorbable CFTR inhibitor Acute secretory diarrhoea Preclinical
Clotrimazole K+ channel inhibitor Acute secretory diarrhoea FDA-approved for other indication
Eluxadoline μ-opioid receptor agonist Diarrhoea- predominant IBD Phase III
Gallotannins CaCC inhibitors Acute secretory diarrhoea Preclinical Nutritional supplement
LX1033 Tryptophan hydroxylase inhibitor; decreased 5-hydroxytryptamine synthesis Diarrhoea- predominant IBD Phase II
Lysophosphatidic acid Lysophosphatidic acid receptor 2 antagonist Acute secretory diarrhoea Preclinical Nutritional supplement
MalH-lectin Inhibitor of the external pore of CFTR Acute secretory diarrhoea Preclinical
NHE3 C-terminal peptide NHE3 regulatory complex agonist Acute secretory diarrhoea Preclinical
Obeticholic acid Semi-synthetic bile acid Bile acid malabsorption diarrhoea Phase II
PPQ/BPO Absorbable CFTR inhibitors Acute secretory diarrhoea Preclinical
R-568 Calcium-sensing receptor agonist Acute secretory diarrhoea Preclinical

Abbreviations: BPO, benzopyrimido-pyrrolo-oxazinedione; CaCC, calcium-activated chloride channel; CFTR, cystic fibrosis transmembrane conductance regulator; NHE, sodium/hydrogen exchanger; PPQ, pyrimido-pyrrolo-quinoxalinedione.